Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Lymphoma, Non-Hodgkin 29Lymphoma 12Lymphoma, Follicular 11Lymphoma, Mantle-Cell 6Lymphoma, Large-Cell, Immunoblastic 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, B-Cell 4Waldenstrom Macroglobulinemia 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Burkitt Lymphoma 3Lymphoma, B-Cell, Marginal Zone 2Multiple Myeloma 1Lymphoma, Large-Cell, Anaplastic 1

Interventions

Dexamethasone 809Bortezomib 449Lenalidomide 430Cyclophosphamide 336Melphalan 251Calcium Dobesilate 237daratumumab 218pomalidomide 202carfilzomib 181fludarabine phosphate 131Thalidomide 121fludarabine 118Peripheral Blood Stem Cell Transplantation 117Filgrastim 111ixazomib 85Mycophenolic Acid 85Granulocyte Colony-Stimulating Factor 84Busulfan 83Whole-Body Irradiation 80Tacrolimus 75dexamethasone acetate 74Cyclosporine 67isatuximab 64Prednisone 64dexamethasone 21-phosphate 63elotuzumab 60auricularum 57belantamab mafodotin 55Antilymphocyte Serum 55Etoposide 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multiple Myeloma × tositumomab I-131 × Clear all
NCT00135200 2025-04-30

Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma

University of Michigan Rogel Cancer Center

Phase 2 Completed
16 enrolled 6 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡